Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $175

Benzinga Newsdesk www.benzinga.com Positive 71.7%

Neg 0% Neu 0% Pos 71.7%

Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $130 to $175.